Accessibility issues or difficulties with this website?
Call 919-962-2073 or email hchsadministration@unc.edu.

American College of Cardiology/American Heart Association (ACC/AHA) Class I Guidelines for the Treatment of Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Implications for US Hispanics/Latinos Based on Findings From the Hispanic Community Heal

TitleAmerican College of Cardiology/American Heart Association (ACC/AHA) Class I Guidelines for the Treatment of Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Implications for US Hispanics/Latinos Based on Findings From the Hispanic Community Heal
Publication TypePublication
Year2017
AuthorsQureshi WT, Kaplan RC, Swett K, Burke G, Daviglus M, Jung M, Talavera GA, Chirinos DA, Reina SA, Davis S, Rodriguez CJ
JournalJ Am Heart Assoc
Volume6
Issue5
Date Published2017 May 11
ISSN2047-9980
KeywordsAdolescent, Adult, Aged, American Heart Association, Atherosclerosis, Biomarkers, Cardiology, Cholesterol, Clinical Decision-Making, Cross-Sectional Studies, Dyslipidemias, Eligibility Determination, Female, Healthcare Disparities, Hispanic or Latino, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Patient Selection, Practice Guidelines as Topic, Prevalence, Risk Factors, United States, Young Adult
Abstract

BACKGROUND: The prevalence estimates of statin eligibility among Hispanic/Latinos living in the United States under the new 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol treatment guidelines are not known.METHODS AND RESULTS: We estimated prevalence of statin eligibility under 2013 ACC/AHA and 3rd National Cholesterol Education Program Adult Treatment Panel (NCEP/ATP III) guidelines among Hispanic Community Health Study/Study of Latinos (n=16 415; mean age 41 years, 40% males) by using sampling weights calibrated to the 2010 US census. We examined the characteristics of Hispanic/Latinos treated and not treated with statins under both guidelines. We also redetermined the statin-therapy eligibility by using black risk estimates for Dominicans, Cubans, Puerto Ricans, and Central Americans. Compared with NCEP/ATP III guidelines, statin eligibility increased from 15.9% (95% CI 15.0-16.7%) to 26.9% (95% CI 25.7-28.0%) under the 2013 ACC/AHA guidelines. This was mainly driven by the ≥7.5% atherosclerotic cardiovascular disease risk criteria (prevalence 13.9% [95% CI 13.0-14.7%]). Of the participants eligible for statin eligibility under NCEP/ATP III and ACC/AHA guidelines, only 28.2% (95% CI 26.3-30.0%) and 20.6% (95% CI 19.4-21.9%) were taking statins, respectively. Statin-eligible participants who were not taking statins had a higher prevalence of cardiovascular risk factors compared with statin-eligible participants who were taking statins. There was no significant increase in statin eligibility when atherosclerotic cardiovascular disease risk was calculated by using black estimates instead of recommended white estimates (increase by 1.4%, =0.12) for Hispanic/Latinos.CONCLUSIONS: The eligibility of statin therapy increased consistently across all Hispanic/Latinos subgroups under the 2013 ACC/AHA guidelines and therefore will potentially increase the number of undertreated Hispanic/Latinos in the United States.

DOI10.1161/JAHA.116.005045
Alternate JournalJ Am Heart Assoc
PubMed ID28495699
PubMed Central IDPMC5524073
MS#: 
0276
Manuscript Lead/Corresponding Author Affiliation: 
Field Center: Bronx (Einstein College of Medicine)
ECI: 
Yes
Manuscript Status: 
Published